medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2024, Number 1

<< Back

Rev Latin Infect Pediatr 2024; 37 (1)

Response to the clinical case: Pneumonia in an immunocompromised pediatric patient

Language: Spanish
References: 15
Page: 57-59
PDF size: 215.30 Kb.





REFERENCES

  1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis. 2002; 8 (9): 891-896. doi: 10.3201/eid0809.020096.

  2. Truong J, Ashurst JV. Pneumocystis jirovecii Pneumonia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.

  3. Calderón Sandubete E, de Armas Rodríguez Y, Capó de Paz V. Pneumocystis jirovecii: cien años de historia [Pneumocystis jirovecii: one hundred years of history]. Rev Cubana Med Trop. 2011; 63 (2): 97-116.

  4. Gigliotti F, Wright TW. Pneumocystis: where does it live? PLoS Pathog. 2012; 8 (11): e1003025. doi: 10.1371/journal.ppat.1003025.

  5. Martín-Pedraz L, Carazo-Gallego B, Moreno-Pérez D. Clinical-epidemiological characteristics of Pneumocystis jirovecii pneumonia in a tertiary hospital in Spain. An Pediatr (Engl Ed). 2021; 95 (1): 4-10. doi: 10.1016/j.anpede.2020.04.023.

  6. Russian DA, Levine SJ. Pneumocystis carinii pneumonia in patients without HIV infection. Am J Med Sci. 2001; 321 (1): 56-65. doi: 10.1097/00000441-200101000-00009.

  7. Bateman M, Oladele R, Kolls JK. Diagnosing Pneumocystis jirovecii pneumonia: A review of current methods and novel approaches. Med Mycol. 2020; 58 (8): 1015-1028. doi: 10.1093/mmy/myaa024.

  8. de Armas-Rodríguez Y, Wissmann G, Müller AL, Pederiva MA, Brum MC, Brackmann RL et al. Pneumocystis jirovecii pneumonia in developing countries. Parasite. 2011; 18 (3): 219-228. doi: 10.1051/parasite/2011183219.

  9. Asai N, Motojima S, Ohkuni Y, Matsunuma R, Nakashita T, Kaneko N et al. Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia. Respir Investig. 2022; 60 (4): 522-530. doi: 10.1016/j.resinv.2022.04.002.

  10. Lagrou K, Chen S, Masur H, Viscoli C, Decker CF, Pagano L et al. Pneumocystis jirovecii disease: basis for the revised EORTC/MSGERC invasive fungal disease definitions in individuals without Human Immunodeficiency Virus. Clin Infect Dis. 2021; 72 (Suppl 2): S114-S120. doi: 10.1093/cid/ciaa1805.

  11. Salzer HJF, Schäfer G, Hoenigl M, Günther G, Hoffmann C, Kalsdorf B et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. Respiration. 2018; 96 (1): 52-65. doi: 10.1159/000487713.

  12. Gronseth S, Rogne T, Hannula R, Asvold BO, Afset JE, Damas JK. Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway. BMC Infect Dis. 2021; 21 (1): 659. doi: 10.1186/s12879-021-06144-1.

  13. Sokulska M, Kicia M, Weso?owska M, Hendrich AB. Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review. Parasitol Res. 2015; 114 (10): 3577-3585. doi: 10.1007/s00436-015-4678-6.

  14. Avino LJ, Naylor SM, Roecker AM. Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacother. 2016; 50 (8): 673-679. doi: 10.1177/1060028016650107.

  15. Mantadakis E. Pneumocystis jirovecii pneumonia in children with hematological malignancies: diagnosis and approaches to management. J Fungi (Basel). 2020; 6 (4): 331. doi: 10.3390/jof6040331.




2020     |     www.medigraphic.com